Several analysts have recently updated their ratings and price targets for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ):

  • 8/30/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $190.00 price target on the stock.
  • 8/29/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 8/29/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Wells Fargo & Company.
  • 8/25/2017 – Jazz Pharmaceuticals PLC is now covered by analysts at HC Wainwright. They set a “neutral” rating and a $144.00 price target on the stock.
  • 8/21/2017 – Jazz Pharmaceuticals PLC was given a new $190.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/10/2017 – Jazz Pharmaceuticals PLC had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $177.00 price target on the stock, down previously from $178.00.
  • 8/10/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $177.00 price target on the stock.
  • 8/9/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Janney Montgomery Scott. They now have a $192.00 price target on the stock, up previously from $180.00.
  • 8/9/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 8/9/2017 – Jazz Pharmaceuticals PLC was given a new $175.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 8/9/2017 – Jazz Pharmaceuticals PLC had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $190.00 price target on the stock.
  • 8/8/2017 – Jazz Pharmaceuticals PLC was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $174.00 price target on the stock. According to Zacks, “Jazz’s largest franchise is its sleep disorder portfolio. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. Moreover, In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. Estimates have been stable lately ahead of the company’s Q2 earnings release.”
  • 8/3/2017 – Jazz Pharmaceuticals PLC was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/17/2017 – Jazz Pharmaceuticals PLC was given a new $178.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 7/14/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $190.00 price target on the stock.
  • 7/14/2017 – Jazz Pharmaceuticals PLC was given a new $182.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded up 0.66% on Wednesday, reaching $148.60. The company had a trading volume of 331,578 shares. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The company has a 50-day moving average price of $150.72 and a 200-day moving average price of $149.42. The firm has a market cap of $8.93 billion, a P/E ratio of 22.89 and a beta of 1.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. The firm had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the business posted $2.67 earnings per share. On average, analysts expect that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current fiscal year.

In other news, Director Patrick G. Enright sold 351 shares of Jazz Pharmaceuticals PLC stock in a transaction on Friday, August 25th. The stock was sold at an average price of $148.40, for a total value of $52,088.40. Following the completion of the sale, the director now directly owns 1,717 shares of the company’s stock, valued at approximately $254,802.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $150.65, for a total value of $30,130.00. Following the completion of the sale, the executive vice president now directly owns 22,223 shares of the company’s stock, valued at $3,347,894.95. The disclosure for this sale can be found here. Insiders sold a total of 7,917 shares of company stock valued at $1,223,227 over the last three months. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.